Alin Albai

Dr. Alin Albai


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Medicina
Verified
Journal Article
Open access
PDF file
ABAdina Braha
Adina Braha
AAAlin Albai
Alin Albai
BTBogdan Timar
Bogdan Timar
SNSerban Mircea Negru
Serban Mircea Negru
SSSorin Saftescu
Sorin Saftescu
DPDorel Popovici
Dorel Popovici
Background and Objectives: The prevalence of cachexia has increased across all of the cancer types and accounts for up to 20% of cancer-related deaths. This paper is a systematic review of nutritional interventions aiming to improve cachexia outcomes in cancer, focusing on weight gain. Materials and Methods: A search in Medline and Elsevier databases for articles up until the 23 January 2022, was conducted. Results: Out of 5732 screened records, 26 publications were included in the final analysis. Four randomized clinical trials showed a significant body weight (BW) increase in patients treated with eicosapentaenoic acid (EPA), β-hydroxy-beta-methyl butyrate (β-HMB), arginine, and glutamine or marine phospholipids (MPL). An upward BW trend was observed in patients treated with L-carnitine, an Ethanwell/Ethanzyme (EE) regimen enriched with ω-3 fatty acids, micronutrients, probiotics, fish oil, a leucine-rich supplement, or total parental nutrition (TPN) with a high dose of a branched-chain amino acid (BCAA). Conclusions: Although clinical trials relating to large numbers of nutritional supplements present promising data, many trials provided negative results. Further studies investigating the underlying mechanisms of action of these nutritional supplements in cancer cachexia are needed. Early screening for cancer cachexia risk and nutritional intervention in cancer patients before aggravating weight loss may stabilize their weight, preventing cachexia syndrome. According to the GRADE methodology, no positive recommendation for these nutritional supplements may be expressed.

26 July 2022 in Medicina
Verified
Journal Article
Open access
PDF file
RPRaul Patrascu
Raul Patrascu
AAAlin Albai
Alin Albai
ABAdina Braha
Adina Braha
LGLaura Gaita
Laura Gaita
SLSandra Lazar
Sandra Lazar
BTBogdan Timar
Bogdan Timar
Background and Objectives: Telemedicine solutions have proven their value and efficacy in augmenting diabetes care. In addition to the availability of tools needed to implement telemedicine solutions for patients with diabetes, the patients’ desirability, acceptance, and adherence represent major burdens in implementing them. The main aim of this research is to evaluate which factors are influencing the desirability, acceptance, and adherence of patients with diabetes to telemedicine interventions in diabetes care. Materials and Methods: QTelemeDiab, a previously validated instrument for assessing patients’ desirability, acceptance, and adherence to telemedicine in diabetes care, was used on 114 enrolled patients with diabetes mellitus, in parallel with demographic, socio-economic, disease history, and psychometric data from all patients. Results: Left-skewed score distributions were observed for the QTelemeDiab total score (median = 166; skewness = −1.738), as well as all its components, thus denoting a high desirability, acceptance, and adherence towards telemedicine use. The presence of severe depression was associated with significant decreases in the QTelemeDiab score (148 vs. 167; p < 0.001), as well as on the desirability sub-score (101 vs. 115; p < 0.001) and adherence sub-score (30 vs. 35; p < 0.001). The presence of severe anxiety was associated with significant decreases in QTelemeDiab score (150 vs. 166), as well as the desirability sub-score (104 vs. 114; p = 0.008) and adherence sub-score (30 vs. 34; p = 0.012). Conclusions: There is a high desirability, acceptance, and adherence to the use of telemedicine interventions in patients with diabetes, both in special and in normal epidemiological settings. The presence of severe anxiety decreases the patient’s desirability, acceptance, and adherence, while the presence of severe depression decreases the patient’s desirability and adherence to the use of telemedicine interventions in diabetes care.

23 December 2021 in Medicina
Verified
Journal Article
Open access
PDF file
ABAdina Braha
Adina Braha
AAAlin Albai
Alin Albai
BTBogdan Timar
Bogdan Timar
DCDaniela Cipu
Daniela Cipu
LVLucian Vasiluță
Lucian Vasiluță
RTRomulus Timar
Romulus Timar
Background and Objectives: Dapagliflozin treatment proved to reduce the epicardial fat volume (EFV) in patients with type 2 diabetes (T2D). Despite the reduction in EFV being associated with improved diastolic function in patients with T2D, EVF is not routinely evaluated in T2D because it is costly and involves radiation exposure. This study aims to identify biomarkers that predict EFV reduction after dapagliflozin treatment in patients with T2D. Materials and Methods: In a prospective, observational, consecutive-case enrollment scenario, 52 patients with T2D were initiated on dapagliflozin 10 mg q.d. as part of the standard of care. At enrollment and after six months of dapagliflozin treatment, patients were evaluated using cardiac ultrasonography, native computer tomography, transient liver elastography, and metabolic lab tests. In addition, the atherogenic index of plasma (AIP), atherogenic coefficient (AC), triglyceride glucose index (TyG), cardiac risk ratio (CRR), and visceral abdominal index (VAI) were calculated. Results: Higher AIP (r = 0.28; p = 0.04), CRR (r = 0.28; p = 0.04), and TyG (r = 0.32; p = 0.01) are associated with more important reductions in the EFV. A lower conicity index (β = −0.29; p = 0.03), visceral fat volume at the 4th vertebrae (L4VFV) (β = −0.32; p = 0.02), left atrium volume (β = −3.08; p = 0.003), and right ventricle diameter (β = −2.13; p = 0.04) are associated with higher reductions in the EFV after six months of dapagliflozin treatment. A valid performance for predicting clinically relevant decreases in EFV after dapagliflozin treatment was observed for AIP (AUROC = 0.903; Youden = 0.732; p < 0.001), CRR (AUROC = 0.772; Youden = 0.595; p = 0.004), TyG (AUROC = 0.957; Youden = 0.904; p < 0.001), and VAI (AUROC = 0.898; Youden = 0.712; p < 0.001). Conclusion: Higher initial EFV values are associated with more important reductions in EFV in patients with T2D treated for six months with dapagliflozin. TyG values have the best prediction performances for EFV reduction, having the highest sum of sensitivity and specificity at the 0.904 threshold level. AIP, CRR, VAI, conicity index, L4VF, left atrium volume, and right ventricle volume are valid biomarkers for a decrease in EFV after dapagliflozin treatment in diabetes patients.

1 December 2021 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
RPRaul Patrascu
Raul Patrascu
AAAlin Albai
Alin Albai
ABAdina Braha
Adina Braha
LGLaura Gaita
Laura Gaita
SLSandra Lazar
Sandra Lazar
BTBogdan Timar
Bogdan Timar
Purpose: To develop, test, and validate an instrument for assessing patients’ desirability, acceptability, and adherence to telemedicine in diabetes. Patients and Methods: A group of six experts defined the components that needed to be assessed when developing telemedicine platforms aimed at improving the care of patients with diabetes. The resulting instrument was tested for reliability and construct validity of 114 patients with diabetes and re-tested for reproducibility and consistency on a sub-group of 34 patients. Based on the analysis, the questionnaire’s syntax, phrasing, and flow were improved to obtain optimal assessment results. Results: The resulting questionnaire has three major sections: one for the main evaluated component (acceptability, desirability, and adherence to telemedicine in diabetes), one for collecting socio-economic and demographical information, and one for diabetes history-related data, respectively. The corresponding data for these sections are collected using 29 questions. The developed instrument has a good reliability (Cronbach’s alpha = 0.890), reproducibility (Total score 164 vs 166 points at re-test vs test; Mann–Whitney U p-value = 0.394) and external validity (Spearman’s rho = − 0.580; p < 0.001 for correlation with Patient’s Health Questionnaire − 9; and Spearman’s rho = − 0.516; p < 0.001 for correlation with Generalized Anxiety Disorder – 7). Conclusion: The developed questionnaire is a valid and reliable instrument in assessing the patients’ acceptability, desirability, and adherence to telemedicine use in diabetes care. In addition, the use of this instrument in the development of telemedicine platforms may improve and optimize their usage by providing valuable information regarding patients’ preferences and specific needs.

25 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IUIon-Vladut Udroiu
Ion-Vladut Udroiu
AAAlin Albai
Alin Albai
SLSandra Lazar
Sandra Lazar
ABAdina Braha
Adina Braha
LGLaura Gaita
Laura Gaita
ASAlexandra Sima
Alexandra Sima
Background/Objectives: The winter holiday period is often associated with lifestyle changes that can affect body composition. This study aimed to evaluate short-term changes in body composition and anthropometric indices over the winter holidays. Methods: A total of 168 adults (126 women and 42 men) were assessed before (December) and after (January) the holidays using bioelectrical impedance analysis (InBody 770) and standard anthropometric measurements. Participants also completed a Healthy Eating Assessment questionnaire to evaluate their dietary habits during this period. Results: After the holiday, statistically significant increases were observed in weight (68.55 → 69.70 kg), body fat mass (20.60 → 21.15 kg), visceral fat area (95.40 → 97.60 cm2), and waist circumference (84.30 → 85.08 cm). Men showed greater gains in weight and fat-related parameters compared to women. Participants who reported healthier dietary behaviors had smaller increases in fat mass and anthropometric measures. Conclusions: These findings suggest that even brief holiday periods can lead to measurable gains in weight and body fat and, if repeated over time, may contribute to the development of obesity.

10 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
IUIon-Vladut Udroiu
Ion-Vladut Udroiu
AAAlin Albai
Alin Albai
SLSandra Lazar
Sandra Lazar
ABAdina Braha
Adina Braha
LGLaura Gaita
Laura Gaita
ASAlexandra Sima
Alexandra Sima
Background and Objectives: Weight gain during winter holidays has been reported in several studies, but most of them focus on short-term changes and rely primarily on body weight or BMI. This study investigates if body composition alterations associated with winter holiday period persist over a one-year follow-up in a Romanian adult population. Materials and Methods: This prospective longitudinal observational study included three assessment points: before the winter holidays (T1), immediately after the holidays (T2), and one year later (T3). Bioelectrical impedance analysis was used to obtain body composition parameters. A total of 120 participants completed all three assessments and were included in the longitudinal analysis. Results: Body weight and visceral fat area increased modestly yet significantly between T1 and T2. At the one-year follow-up, values remained similar to those observed immediately after the holiday period, suggesting persistence at group level (body weight: 68.25 → 69.40 → 69.45 kg and visceral fat area: 98.49 → 100.54 → 101.42 cm2). The net change observed during the holiday period was similar in magnitude to the overall annual difference. Changes in body weight were significantly associated with changes in visceral fat both during the holiday period and across the entire follow-up. Conclusions: Modest increases in body weight and visceral fat observed during the winter holidays were still present at one year. These findings suggest that short seasonal periods may contribute to overall annual changes in body weight and fat distribution.